Company intelligence / Profile preview

BrYet US

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

BrYet is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for cancer. The company utilizes its proprietary Targeted Delivery System (TDS) platform to enhance the efficacy and reduce the toxicity of established chemotherapeutic agents. Its lead candidate, BRY-801, is a folate-receptor-targeted formulation of paclitaxel currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors, including ovarian and triple-negative breast cancers. BrYet aims to transform cancer treatment by delivering potent drugs directly to tumor cells while sparing healthy tissue.

Therapeutic areas: Oncology
Modalities: Small moleculeNanoparticleTargeted drug delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on BrYet US.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrYet US.

Explore the full profile